Letters to the Editor

CD19 antigen: from tumor target to safety switch in CAR-T cell therapy

Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy; Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome
Cancer Gene Therapy Unit, Onco-Hematology Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy; Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples
Haematologica Early view Aug 27, 2026 https://doi.org/10.3324/haematol.2026.301013